DOCSLIB.ORG

Evolution of the Vasopressin/Oxytocin Superfamily

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Evolution of the Vasopressin/Oxytocin Superfamily Proc. Nadl. Acad. Sci. USA Vol. 89, pp. 4593-4597, May 1992 Neurobiology Evolution of the vasopressin/oxytocin superfamily: Characterization of a cDNA encoding a vasopressin-related precursor, preproconopressin, from the mollusc Lymnaea stagnalis (gastropod mollusc/neuropeptide/conopressin/neurophysln/prohormone organization) RONALD E. VAN KESTEREN*t, AUGUST B. SMIT*, ROELAND W. DIRKSI, Nico D. DE WITH*, WUNAND P. M. GERAERTS*, AND JOOS JOOSSE* *Faculty of Biology, Unit Molecular Neurobiology/Endocrinology, Vrije Universiteit, De Boelelaan 1087, 1081 HV Amsterdam, The Netherlands; and tDepartment of Cytochemistry and Cytometry, University of Leiden, Wassenaarseweg 72, 2333 AC Leiden, The Netherlands Communicated by Berta Scharrer, December 27, 1991 ABSTRACT Although the nonapeptide hormones vaso- thought that these genes evolved from an ancestral gene about pressin, oxytocin, and related peptides from vertebrates and 400 million years ago (6, 7). The prohormones contain, in some nonapeptides from invertebrates share smilities in addition to the nominal peptide domain, a highly conserved amino acid sequence, their evolutionary relationships are not cysteine-rich neurophysin domain, which probably is involved dear. To investigate this issue, we doned a cDNA encoding a in binding ofthe hormones during axonal transport. The mam- vasopressin-related peptide, Lys-conopressin, produced in the malian vasopressin precursor further includes a copeptin do- central nervous system of the gastropod mollusc Lymnaea main that is cleaved off and may play a role as a prolactin stagnalis. The predicted preproconopressin has the overall releasing factor (8). This copeptin domain is entirely absent in architecture of vertebrate preprovasopressins, with a signal the oxytocin precursor and is represented as a C-terminal highly peptide, Lys-conopressin, that is flanked at the C terminus by divergent extension of the neurophysin domain in the vaso- an amidation signal and a pair of basic residues, followed by a pressin-related precursors of lower vertebrates. neurophysin domain. The Lymnaea neurophysin and the ver- The high identity in amino acid sequence of the vertebrate tebrate neurophysins share high sequence identity, which and invertebrate peptides has led to the hypothesis that the includes the conservation of all 14 cysteine residues. In addi- vasopressin/oxytocin superfamily may have evolved from a tion, the Lymnaea neurophysin possesses unique structural common ancestral form, ofwhich the nature ofthe precursor characteristics. It contains a putative N-linked glycosylation and gene is unknown. To further investigate the evolutionary site at a position in the vertebrate neurophysins where a strictly origin ofthe vasopressin/oxytocin superfamily, we have now conserved tyrosine residue, which plays an essential role in cloned and sequenced the cDNA encoding conopressin from binding ofthe nonapeptide hormones, is found. The C-terminal Lymnaea.§ Our analysis ofthe deduced amino acid sequence copeptin homologous extension of the Lymnaea neurophysin for Lymnaea preproconopressin indicates that it is organized has low sequence identity with the vertebrate counterparts and much like the vasopressin (related) precursors of the verte- is probably not cleaved from the prohormone, as are the brates, with a signal sequence followed by conopressin and mammalin copeptins. The conopressin gene is expressed in a remarkably conserved neurophysin domain having a diver- only a few neurons in both pedal ganglia of the central nervous gent copeptin-homologous C-terminal sequence. Thus, we system. The conopressin transcript is present in two sizes, due could unequivocally demonstrate that the typical architec- to alternative use of polyadenylylation signals. The data pre- ture of the precursors of the vasopressin/oxytocin hormone sented here demonstrate that the typical organization of the superfamily must have been present in the Archaemetazoa, prohormones of the vasopressin/oxytocin superfamily must a stem group from which both the vertebrates and inverte- have been present in the common ancestors of vertebrates and brates diverged about 600 million years ago. invertebrates. The vasopressin/oxytocin hormone superfamily includes va- MATERIALS AND METHODS sopressin, oxytocin, and related peptides in vertebrates and Animals. Adult Lymnaea stagnalis (shell height, 28-34 in invertebrates (ref. 1; Fig. 1). Invertebrate members include mm), bred in the laboratory under standard conditions (9), the vasopressin-like diuretic hormone from the locust Lo- were used. custa migratoria (2), the conopressins from the gastropod PCR. Two degenerate oligonucleotides, oligo 1 and oligo 2, molluscs Conus geographus, Conus striatus (3), and Lym- were synthesized, based on the amino acid sequence of naea stagnalis (unpublished observations) and cephalotocin Lymnaea conopressin [oligo 1, 5'-CCAAGCTTTG(CT)TT- from the cephalopod mollusc Octopus vulgaris (4). All of (CT)AT(ACT)(AC)G(GATC)AA(CT)TG(CT)CC-3'; oligo 2, these hormones are nonapoptides that share close similarities 5'-CCAAGCTTAA(CT)TG(CT)CC(GATC)AA(GA)GG- in primary and tertiary structure. Biological activity may (GATC)GG-3']. Both oligonucleotides were provided with differ, however, mainly due to the amino acid residue in HindIII restriction site extensions on the 5' ends and were position 8, which is a basic amino acid in vasopressin and used as primers in a PCR, with cDNA isolated from a AgtlO vasopressin-related peptides and a neutral amino acid in cDNA library of the central nervous system (CNS) (10) as oxytocin and oxytocin-related peptides. template. As reverse primer, the A oligo was used that is In vertebrates, vasopressin, oxytocin, and related peptides complementary to a sequence in the left arm ofAgtlO (A oligo, are encoded by two types of structurally related genes and 5'-AGCAAGTTCAGCCTGGTTAAGTCC-3'). In the first synthesized as part of larger precursor molecules (5). It is Abbreviations: CNS, central nervous system; nt, nucleotide(s). The publication costs of this article were defrayed in part by page charge tTo whom reprint requests should be addressed. payment. This article must therefore be hereby marked "advertisement" §The sequence reported in this paper has been deposited in the in accordance with 18 U.S.C. §1734 solely to indicate this fact. GenBank data base (accession no. M86610). 4593 . Downloaded by guest on September 26, 2021 4594 Neurobiology: van Kesteren et al. Proc. Natl. Acad Sci. USA 89 (1992) vasopressin(-related) peptides Cys Phe Ile Arg Asn Cya Pro Lys Gly-NH2 Lys-conopressin Lymnaea stagnalis, Conus geographus Cys Ile Ile Arg Ann Cys Pro Arg Gly-NH2 Arg-conopressin Conus striatus Cys Leu Ile Thr Ann Cys Pro Arg Gly-N82 diuretic hormone Locustanmgratoria Cys Tyr Ile Gln Aan Cys Pro Arg Gly-N12 vasotocin non-mammalian vertebrates Cys Tyr Phe Gln A n Cys Pro Arg Gly-N32 Arg-vasopressin mammals Cys Tyr Phe Gln Ann Cys Pro Lys Gly-NE2 Lys-vasopressin mammals Cys Phe Phe Gln Ann Cys Pro Arg Gly-NR2 phenypressin mammals oxytocin(-related) peptides Cys Tyr Phe Arg An Cys Pro Ile Gly-NH2 Cephalotocin Octopus vulgaris Cys Tyr Ile Asn An Cya Pro Leu Gly-NB2 Aspargtocin cartilaginous fishes (sharks) Cya Tyr Ile Gln An Cys Pro Val Gly-NE2 Valitocin cartilaginous fishes (sharks) Cys Tyr Ile Ser An Cya Pro Gln Gly-NH2 Glumitocin cartilaginous fishes (rays) Cys Tyr Ile Ser An Cya Pro Ile Gly-NH2 Isotocin bony fishes Cys Tyr Ile Gln An Cy. Pro Ile Gly-NH2 Mesotocin mammals, birds, reptiles, amphibians, lungfishes Cys Tyr Ile Gln An Cya Pro Leu Gly-NH2 Oxytocin mammals 1 2 3 4 5 6 7 8 9 FIG. 1. Compilation of the primary sequences of various peptides of the vasopressin/oxytocin superfamily. Residues at positions 1, 5, 6, 7, and 9 that are shared by all members ofthe superfamily are indicated in boldface type. Each peptide is indicated by name and by species/group in which it has been identified. PCR, cDNA was amplified between oligo 1 and the A oligo by 3' part ofthe mRNA encoding the conopressin region and the using 30 cycles: 940C for 1 min, 450C for 1 min, and 720C for hypothetical neurophysin region of the preprohormone. A 2 min. After amplification, 5 uml of the PCR mixture were degenerate oligonucleotide primer that corresponds to the reamplified under the same conditions, but using oligo 2 and N-terminal part ofconopressin and an oligonucleotide primer the A oligo. Amplified cDNA was digested with EcoRI and that is complementary to a sequence in the left arm of AgtlO HindIll, subcloned, and sequenced. were used to amplify cDNA from a AgtlO cDNA library ofthe Labeling of the Conopressin cDNAs. Radiolabeled cDNA CNS of Lymnaea stagnalis. Analysis of the PCR mixture by was synthesized by primer extension on a single-stranded electrophoresis on an agarose gel revealed many products. M13 clone containing a conopressin cDNA derived either by To increase the specificity of the PCR, a degenerate oligo- PCR or from AgtlO. An M13-specific primer was used, and part of [a-32P~dATP was incorporated during the reaction. The spe- nucleotide primer that corresponds to the C-terminal cific activity of the probes was >2 x 108 dpm/pug. conopressin and the same A oligonucleotide primer were used Screening of the cDNA Library. Approximately 2 x 10l to amplify the cDNA mixture of the first round of amplifi- recombinant AgtlO phages from a CNS-specific cDNA library cation. Analysis of the second PCR mixture on agarose gel (10) were plated at 7 x 104 plaques per 245 x 245 mm dish and revealed a major product of700 base pairs, which was cloned absorbed to Hybond-N filters (Amersham). After prehybrid- in M13mpl8 and sequenced. It appeared to contain the PCR ization, the filters were hybridized with the radiolabeled primer followed by an open reading frame encoding the conopressin cDNA (derived by the PCR) for 16 h, washed in endoproteolytic processing site Lys-Arg and a large cysteine- 2x SSC (lx SSC = 150 mM NaCl/15 mM sodium citrate, pH rich peptide. The first 9 amino acids of this peptide had only 7.4)/0.1% SDS at 650C for 30 min, and autoradiographed.
Load more

Recommended publications
  • Oxytocin Is an Anabolic Bone Hormone
    Oxytocin is an anabolic bone hormone Roberto Tammaa,1, Graziana Colaiannia,1, Ling-ling Zhub, Adriana DiBenedettoa, Giovanni Grecoa, Gabriella Montemurroa, Nicola Patanoa, Maurizio Strippolia, Rosaria Vergaria, Lucia Mancinia, Silvia Coluccia, Maria Granoa, Roberta Faccioa, Xuan Liub, Jianhua Lib, Sabah Usmanib, Marilyn Bacharc, Itai Babc, Katsuhiko Nishimorid, Larry J. Younge, Christoph Buettnerb, Jameel Iqbalb, Li Sunb, Mone Zaidib,2, and Alberta Zallonea,2 aDepartment of Human Anatomy and Histology, University of Bari, 70124 Bari, Italy; bThe Mount Sinai Bone Program, Mount Sinai School of Medicine, New York, NY 10029; cBone Laboratory, The Hebrew University of Jerusalem, Jerusalem 91120, Israel; dGraduate School of Agricultural Science, Tohoku University, Aoba-ku, Sendai, Miyagi 981-8555 Japan; and eCenter for Behavioral Neuroscience, Department of Psychiatry, Emory University School of Medicine, Atlanta, GA 30322 Communicated by Maria Iandolo New, Mount Sinai School of Medicine, New York, NY, February 19, 2009 (received for review October 24, 2008) We report that oxytocin (OT), a primitive neurohypophyseal hor- null mice (5). But the mice are not rendered diabetic, and serum mone, hitherto thought solely to modulate lactation and social glucose homeostasis remains unaltered (9). Thus, whereas the bonding, is a direct regulator of bone mass. Deletion of OT or the effects of OT on lactation and parturition are hormonal, actions OT receptor (Oxtr) in male or female mice causes osteoporosis that mediate appetite and social bonding are exerted centrally. resulting from reduced bone formation. Consistent with low bone The precise neural networks underlying OT’s central effects formation, OT stimulates the differentiation of osteoblasts to a remain unclear; nonetheless, one component of this network mineralizing phenotype by causing the up-regulation of BMP-2, might be the interactions between leptin- and OT-ergic neurones which in turn controls Schnurri-2 and 3, Osterix, and ATF-4 expres- in the hypothalamus (10).
    [Show full text]
  • E001466.Full.Pdf
    Editorial BMJ Glob Health: first published as 10.1136/bmjgh-2019-001466 on 11 April 2019. Downloaded from WHO recommendations on uterotonics for postpartum haemorrhage prevention: what works, and which one? Joshua P Vogel, 1,2 Myfanwy Williams,3 Ioannis Gallos,4 Fernando Althabe,1 Olufemi T Oladapo1 To cite: Vogel JP, THE GLOBAL BURDEN OF POSTPARTUM trials of tranexamic acid for PPH treatment Williams M, Gallos I, et al. HAEMORRHAGE and a heat-stable formulation of carbetocin WHO recommendations on 6–12 uterotonics for postpartum Obstetric haemorrhage, especially post- for PPH prevention. The increasing haemorrhage prevention: partum haemorrhage (PPH), was responsible number of PPH prevention and management what works, and which for more than a quarter of the estimated 303 options makes it challenging for providers one?BMJ Glob Health 000 maternal deaths that occurred globally in and health system stakeholders to choose 2019;4:e001466. doi:10.1136/ 2015.1 PPH—commonly defined as a blood where and how to invest limited resources in bmjgh-2019-001466 loss of 500 mL or more within 24 hours after order to optimise health outcomes. birth—affects about 6% of all women giving Multiple uterotonics have been eval- Handling editor Seye Abimbola birth.1 Uterine atony is the most common uated for PPH prevention over the past Received 4 February 2019 cause of PPH, but it can also be caused by four decades, including oxytocin receptor Revised 10 March 2019 genital tract trauma, retained placental tissue agonists (oxytocin and carbetocin), prosta- Accepted 16 March 2019 or maternal bleeding disorders. The majority glandin analogues (misoprostol, sulprostone, of women who experience PPH have no iden- carboprost), ergot alkaloids (such as ergo- tifiable risk factor, meaning that PPH preven- metrine/methylergometrine) and combina- tion programmes rely on universal use of PPH tions of these (oxytocin plus ergometrine, © Author(s) (or their prophylaxis for all women in the immediate or oxytocin plus misoprostol).
    [Show full text]
  • Oxytocin Carbetocin
    CARBETOCIN To prevent life-threatening pregnanCy CompliCations Postpartum haemorrhage (PPH) is commonly defined as a blood loss of at least 500 ml within 24 hours after birth, and affects about 5% of all women giving birth around the world. Globally, nearly one quarter of all maternal deaths are associated with PPH, and in most low-income countries it is the main cause of maternal mortality. The use of good quality prophylactic uterotonics can avoid the majority of PPH-associated complications during the third stage of labor (the time between the birth of the baby and complete expulsion of the placenta). In settings where oxytocin is unavailable or its quality cannot be guaranteed, the use of other injectable uterotonics (carbetocin, or if appropriate ergometrine/methylergometrine, or oxytocin and ergometrine fixed-dose combination) or oral misoprostol is recommended for the prevention of PPH. The use of carbetocin (100 μg, IM/IV) is recommended for the prevention of PPH for all births in contexts where its cost is comparable to other effective uterotonics. Carbetocin is only recommended for the prevention of postpartum hemorrhage and not recommended for other obstetric indications, such as labor induction, labor augmentation or treatment of PPH. OXYTOCIN Mode of Action CARBETOCIN Synthetic cyclic peptide form of the Long-acting synthetic analogue of naturally occurring posterior oxytocin with agonist properties. pituitary hormone. Binds to oxytocin Binds to oxytocin receptors in the receptors in the uterine myometrium, uterine smooth muscle, resulting in stimulating contraction of this rhythmic contractions, increased uterine smooth muscle by increasing frequency of existing contractions, the sodium permeability of uterine and increased uterine tone.
    [Show full text]
  • Reorganization of Neural Peptidergic Eminence After Hypophysectomy
    The Journal of Neuroscience, October 1994, 14(10): 59966012 Reorganization of Neural Peptidergic Systems Median Eminence after Hypophysectomy Marcel0 J. Villar, Bjiirn Meister, and Tomas Hiikfelt Department of Neuroscience, The Berzelius Laboratory, Karolinska Institutet, Stockholm, 171 77 Sweden Earlier studies have shown the formation of a novel neural crease to a final stage of a few, strongly immunoreactive lobe after hypophysectomy, an experimental manipulation fibers in the external layer at longer survival times. Vaso- that causes transection of neurohypophyseal nerve fibers active intestinal polypeptide (VIP)- and peptide histidine- and removal of pituitary hormones. The mechanisms that isoleucine (PHI)-IR fibers in hypophysectomized animals had underly this regenerative process are poorly understood. already contacted portal vessels 5 d after hypophysectomy, The localization and number of peptide-immunoreactive and from then on progressively increased in numbers. Fi- (-IR) fibers in the median eminence were studied in normal nally, most of the peptide fibers described above formed rats and in rats at different times of survival after hypophy- dense innervation patterns around the large blood vessels sectomy using indirect immunofluorescence histochemistry. along the lateral borders of the median eminence. The number of vasopressin (VP)-IR fibers increased in the The present results show that hypophysectomy induces external layer of the median eminence in 5 d hypophysec- a wide variety of changes in hypothalamic neurosecretory tomized rats. Oxytocin (OXY)-IR fibers decreased in the in- fibers. Not only is the expression of several peptides in these ternal layer and progressively extended into the external fibers modified following different survival times, but a re- layer.
    [Show full text]
  • Oxytocin Effects in Mothers and Infants During Breastfeeding
    © 2013 SNL All rights reserved REVIEW Oxytocin effects in mothers and infants during breastfeeding Oxytocin integrates the function of several body systems and exerts many effects in mothers and infants during breastfeeding. This article explains the pathways of oxytocin release and reviews how oxytocin can affect behaviour due to its parallel release into the blood circulation and the brain. Oxytocin levels are higher in the infant than in the mother and these levels are affected by mode of birth. The importance of skin-to-skin contact and its association with breastfeeding and mother-infant bonding is discussed. Kerstin Uvnäs Moberg Oxytocin – a system activator increased function of inhibitory alpha-2 3 MD, PhD xytocin, a small peptide of just nine adrenoceptors . Professor of Physiology amino acids, is normally associated The regulation of the release of oxytocin Swedish University of Agriculture O with labour and the milk ejection reflex. is complex and can be affected by different [email protected] However, oxytocin is not only a hormone types of sensory inputs, by hormones such Danielle K. Prime but also a neurotransmitter and a as oestrogen and even by the oxytocin 1,2 molecule itself. This article will focus on PhD paracrine substance in the brain . During Breastfeeding Research Associate breastfeeding it is released into the brain of four major sensory input nervous Medela AG, Baar, Switzerland both mother and infant where it induces a pathways (FIGURES 2 and 3) activated by: great variety of functional responses. 1. Sucking of the mother’s nipple, in which Through three different release pathways the sensory nerves originate in the (FIGURE 1), oxytocin functions rather like a breast.
    [Show full text]
  • Physiology of Hypothalamus and Pituitary
    Physiology of Hypothalamus and Pituitary Simge Aykan, PhD Department of Physiology Ankara University School of Medicine Pituitary Gland • Pituitary gland (hypophysis) is two different tissue types that merged during embryonic development • Anterior pituitary (adenohypophysis): true endocrine gland of epithelial origin • Posterior pituitary (neurohypophysis): extension of the neural tissue of the brain • secretes neurohormones made in the hypothalamus Pituitary Gland • Pituitary bridges and integrates the neural and endocrine mechanisms of homeostasis. • Highly vascular • Posterior pituitary receives arterial blood • anterior pituitary receives only portal venous inflow from the median eminence. • Portal system is particularly important in its function of carrying neuropeptides from the hypothalamus and pituitary stalk to the anterior pituitary. Posterior Pituitary • Storage and release site for two neurohormones (peptide hormones) • Oxytocin • Vasopressin (antidiuretic hormone; ADH) • Large diameter neurons producing hormones are clustered in hypothalamus at paraventricular (oxytocin) and supraoptic nuclei (ADH) • Secretory vesicles containing neurohormones transported to posterior pituitary through axons of the neurons • Stored at the axons until a release signal arrives • Depolarization of the axon terminal opens voltage gated Ca2+ channels and exocytosis is triggered • Hormones release to the circulation Posterior Pituitary • The posterior pituitary regulates water balance and uterine contraction • Vasopressin (ADH), is a neuropeptide
    [Show full text]
  • Antitumor Effects of Desmopressin in Combination with Chemotherapeutic Agents in a Mouse Model of Breast Cancer GISELLE V
    ANTICANCER RESEARCH 28 : 2607-2612 (2008) Antitumor Effects of Desmopressin in Combination with Chemotherapeutic Agents in a Mouse Model of Breast Cancer GISELLE V. RIPOLL, SANTIAGO GIRON, MARTIN J. KRZYMUSKI, GUILLERMO A. HERMO, DANIEL E. GOMEZ and DANIEL F. ALONSO Laboratory of Molecular Oncology, Department of Science and Technology, Quilmes National University, Buenos Aires, Argentina Abstract. The vasopressin peptide analog desmopressin has cytotoxicity on tumor cells, suggesting that the compound been used during surgery to prevent bleeding in patients with modulates a complex biological mechanism on the host coagulation defects. Recent experimental and clinical data which influences tumor spread. We further demonstrated that revealed that perioperative desmopressin therapy can perioperative administration of DDAVP dramatically reduced minimize the spread and survival of residual cancer cells. lymph node and lung metastasis in a model of mammary Here, we explored the antitumor effects of desmopressin in tumor manipulation and surgical excision in mice (6). More combination with chemotherapeutic agents using the F3II recently, a veterinary clinical study showed that perioperative mammary carcinoma in syngeneic Balb/c mice. Intravenous DDAVP prolonged disease-free survival in surgically treated administration of desmopressin at a dose of 2 μg/kg together bitches with locally advanced mammary cancer (7). with weekly cycles of carmustine (20 mg/kg) prevented Breast cancer is one of the most commonly diagnosed primary tumor infiltration of the skin. Combination of malignanc ies in women and mortality for the disease is related desmopressin with paclitaxel (25 mg/kg) significantly reduced to the capacity of breast tumor cells to invade and metastasize. metastatic progression to the lung.
    [Show full text]
  • Effect of Early Vasopressin Vs Norepinephrine On
    Protocol Number: CRO1888 VANISH Vasopressin vs Noradrenaline as Initial therapy in Septic Shock PROTOCOL NUMBER: CRO1888 EudraCT NUMBER: 2011-005363-24 SPONSOR: Imperial College London FUNDER: National Institute for Health Research DEVELOPMENT PHASE: PHASE IV STUDY COORDINATION CENTRE: Imperial Clinical Trials Unit PROTOCOL Version & Date: Version 2.1, 02.08.2013 Property of: Dr Anthony Gordon May not be used, divulged or published without the consent of: Dr Anthony Gordon Confidential Final Version2.1, 02.08.2013 Page 1 of 31 Downloaded From: https://jamanetwork.com/ on 09/29/2021 Protocol Number: CRO1888 Study Management Group Chief Investigator: Dr Anthony Gordon Co-investigators: Dr Stephen Brett Prof Gavin Perkins Prof Deborah Ashby Statistician: Dr Alexina Mason Trial Management: Ms Neeraja Thirunavukkarasu Study Coordination Centre For general queries, supply of trial documentation, and collection of data, please contact: Study Coordinator: Ms Neeraja Thirunavukkarasu Address: ICU – 11N, Charing Cross Hospital, Fulham Palace Road London W6 8RF E-mail: [email protected] Clinical Queries Clinical queries should be directed to Ms Neeraja Thirunavukkarasu who will direct the query to the appropriate person Sponsor Imperial College London is the main research Sponsor for this study. For further information regarding the sponsorship conditions, please contact the Head of Regulatory Compliance at: Joint Research Compliance Office 510, Lab block, 5th Floor Charing Cross Hospital Fulham Palace Road London W6 8RF Tel: 0203 311 0213 Fax: 0203 311 0203 Funder National Institute for Health Research – Research for Patient Benefit and Clinician Scientist award schemes This protocol describes the VANISH study and provides information about procedures for entering participants.
    [Show full text]
  • Vasopressin V2 Is a Promiscuous G Protein-Coupled Receptor That Is Biased by Its Peptide Ligands
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.28.427950; this version posted January 28, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Vasopressin V2 is a promiscuous G protein-coupled receptor that is biased by its peptide ligands. Franziska M. Heydenreich1,2,3*, Bianca Plouffe2,4, Aurélien Rizk1, Dalibor Milić1,5, Joris Zhou2, Billy Breton2, Christian Le Gouill2, Asuka Inoue6, Michel Bouvier2,* and Dmitry B. Veprintsev1,7,8,* 1Laboratory of Biomolecular Research, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland and Department of Biology, ETH Zürich, 8093 Zürich, Switzerland 2Department of Biochemistry and Molecular medicine, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada 3Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305, USA 4The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, United Kingdom 5Department of Structural and Computational Biology, Max Perutz Labs, University of Vienna, Campus-Vienna-Biocenter 5, 1030 Vienna, Austria 6Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi 980-8578, Japan. 7Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, UK. 8Division of Physiology, Pharmacology & Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, NG7 2UH, UK. *Correspondence should be addressed to: [email protected], [email protected], [email protected].
    [Show full text]
  • The Oxytocin Receptor Gene (OXTR) Is Associated with Autism Spectrum Disorder: a Meta-Analysis
    Molecular Psychiatry (2015) 20, 640–646 © 2015 Macmillan Publishers Limited All rights reserved 1359-4184/15 www.nature.com/mp ORIGINAL ARTICLE The oxytocin receptor gene (OXTR) is associated with autism spectrum disorder: a meta-analysis D LoParo and ID Waldman The oxytocin receptor gene (OXTR) has been studied as a risk factor for autism spectrum disorder (ASD) owing to converging evidence from multiple levels of analysis that oxytocin (OXT) has an important role in the regulation of affiliative behavior and social bonding in both nonhuman mammals and humans. Inconsistency in the effect sizes of the OXTR variants included in association studies render it unclear whether OXTR is truly associated with ASD, and, if so, which OXTR single-nucleotide polymorphisms (SNPs) are associated. Thus, a meta-analytic review of extant studies is needed to determine whether OXTR shows association with ASD, and to elucidate which specific SNPs have a significant effect on ASD. The current meta-analysis of 16 OXTR SNPs included 3941 individuals with ASD from 11 independent samples, although analyses of each individual SNP included a subset of this total. We found significant associations between ASD and the SNPs rs7632287, rs237887, rs2268491 and rs2254298. OXTR was also significantly associated with ASD in a gene-based test. The current meta-analysis is the largest and most comprehensive investigation of the association of OXTR with ASD and the findings suggest directions for future studies of the etiology of ASD. Molecular Psychiatry (2015) 20, 640–646; doi:10.1038/mp.2014.77; published online 5 August 2014 INTRODUCTION sizes.8 Nevertheless, several genes and genomic regions have Autism spectrum disorder (ASD) refers to a group of neuro- shown relatively consistent association with ASD.
    [Show full text]
  • Vasopressin Versus Norepinephrine in Septic Shock: a Propensity Score Matched Efficiency Retrospective Cohort Study in the VASST Coordinating Center Hospital James A
    Russell et al. Journal of Intensive Care (2018) 6:73 https://doi.org/10.1186/s40560-018-0344-2 RESEARCH Open Access Vasopressin versus norepinephrine in septic shock: a propensity score matched efficiency retrospective cohort study in the VASST coordinating center hospital James A. Russell1,2*, Hugh Wellman3 and Keith R. Walley1,2 Abstract Purpose: It is not clear whether vasopressin versus norepinephrine changed mortality in clinical practice in the Vasopressin and Septic Shock Trial (VASST) coordinating center hospital after VASST was published. We tested the hypothesis that vasopressin changed mortality compared to norepinephrine using propensity matching of vasopressin to norepinephrine-treated patients in the VASST coordinating center hospital before (SPH1) and after (SPH2) VASST was published. Methods: Vasopressin-treated patients were propensity score matched to norepinephrine-treated patients based on age, APACHE II, respiratory, renal, and hematologic dysfunction, mechanical ventilation status, medical/surgical status, infection site, and norepinephrine dose. The propensity score estimated the probability that a patient would have received vasopressin given baseline characteristics. For sensitivity analysis, we then excluded patients who had underlying severe congestive heart failure. The primary outcome was 28-day mortality. Results: Vasopressin- and norepinephrine-treated patients were similar after matching in SPH1 (pre-VASST); vasopressin-treated patients (n = 158) had a significantly higher mortality than norepinephrine-treated patients (n = 158) (60.8 vs. 46.2%, p = 0.009). In SPH2 after matching, the 28-day mortality rates were not significantly different; 31.2% and 26.9% in the vasopressin (n = 93) and norepinephrine (n = 93) groups, respectively (p = 0.518). The day 1 vasopressin dose in SPH1 vs.
    [Show full text]
  • Influence of Demoxytocin on the Behavioural Actions of Melatonin Manoj G
    Journal of Experimental Sciences 2011, 2(8): 07-09 ISSN: 2218-1768 www.scholarjournals.org www.jexpsciences.com JES-Life Sciences Influence of Demoxytocin on the Behavioural Actions of Melatonin Manoj G. Tyagi* and M. Selva Murugan Department of Pharmacology, Christian Medical College, Vellore 632002, Tamilnadu, India Article Info Abstract Article History Oxytocin is stored and released by the posterior pituitary gland. In this study, the influence of Received : 05-05-2011 oxytocin agonist, demoxytocin pretreatment on the behavioural actions of melatonin was Revised : 27-07-2011 ascertained. Swiss albino mice (n=6) were used for this study as control and test groups. Accepted : 27-07-2011 Demoxytocin was injected in a concentration of (20 I.U/kg, i.p) and melatonin was injected (200μg/kg, i.p) 30 minutes before experimentation. The effect of pretreatment with *Corresponding Author demoxytocin was evaluated after melatonin injection on motor-coordination and locomotor Tel : +91-416-2284237 activity. The results of our study suggest that demoxytocin was not able to affect significantly Fax : +91-416-2284237 the actions on motor co-ordination but attenuated the locomotor activity after melatonin Email: treatment. [email protected] ©ScholarJournals, SSR Introduction Oxytocin has been shown to have a role in social was approved by the Institutional Review Board (IRB) and care separation and related stress. Oxytocin serves important roles of animals was taken as per guidelines of CPCSEA, in behaviour regulation and plays important role in emotional Department of Animal Welfare, Government of India. and social bonding (Landgraf, 1995). Oxytocin receptor is Drugs and Chemicals expressed in the central nervous system and is a G protein Melatonin tablets were obtained from Aristo coupled receptor.
    [Show full text]